Créer mon blog M'identifier

SRA-ribonucleic acid recognition and antimicrobial drug discovery

Le 2 décembre 2016, 10:58 dans Humeurs 0

 

Medicilon offers fully integrated pharmaceutical services for the global scientific community. We focus on providing an exceptional client-centered experience and advancing the drug discovery process.

Email: Marketing@medicilon.com.cn                    Website: www.medicilon.com

The interaction of a protein with endogenous ligands is at the heart of developing new chemotherapeutic agents; emulating how a ligand binds within a known target macromolecular active site is essential to drug discovery. In the following work, several aspects of drug design are enlightened, including structural-based drug design, structural determination and binding interface identification, and fragment-based drug discovery (FBDD). Primarily is the proposal of a new anti-viral drug candidate for the Influenza A virus, which is a structural-based drug design project employing a carbon-sulfur atom switch. This allows for a more suitable fit in the molecular space allotted in the binding site provided by the known target, the matrix 2 (AM2) proton channel. Understanding how the adamantanes interact with the binding site was essential in the design of this proposed drug candidate, 2,4,9-trithiaadamante-7-amine. Another aspect of drug design is the structural identification of a target, as seen in the second project; the work investigates epigenetic changes and how they occur via interactions between a known long non-coding RNA (lncRNA), the steroid receptor activator (SRA) RNA and the RNA recognition motif (RRM) 1 of the SMRT/HDAC1 Associated Repressor Protein SHARP with the distant objective of developing a small molecule chemotherapeutic agent. This involves the solution structure determination of SHARP1P82*, with the determination of the binding interface between the domain and the region of SRA RNA stem loop region 7 (STR7).

 

Lastly, an FBDD project is explored using the glutaredoxin protein system as the known target. The ortholog glutaredoxins, human glutaredoxin 1 (hGRX), and bacterial Brucella melitensis (brmGRX) and Pseudomonas aergunisa (paGRX) are essential proteins with anti-oxidative roles. There are several health risks involving these proteins and the misbalance of the redox system, including Brucella ovis (Malta fever), and cystic fibrosis (CF). Fragments optimization with the goal of developing a small molecule selective inhibitor is an essential aspect to FBDD. The scope of the research spans several phases of the process of drug discovery, from structural-based drug design to the structural determination of the binding target site, and lastly, to insights into the rapid growth of drug design via FBDD methods.

Tracing Safety and Efficacy in Mef-Lariam's Licensure

Le 2 décembre 2016, 10:58 dans Humeurs 0

 

Medicilon offers fully integrated pharmaceutical services for the global scientific community. We focus on providing an exceptional client-centered experience and advancing the drug discovery process.

Email: Marketing@medicilon.com.cn                    Website: www.medicilon.com

The Walter Reed Institute of Army Research developed the antimalarial drug mefloquine then collaborated with Hoffman-La Roche to produce the drug under its brand name “Lariam,” after Food and Drug Administration (FDA) approved licensure in 1989. For over twenty years, the Army used this pill as its “drug of choice” for soldiers deployed to endemic regions until 2009, and in 2013 the Food and Drug Administration warned that the drug’s neurotoxic effects could be lasting, if not permanent. The sociopolitical exigence of developing a new biochemical antimalarial drug rushed the development and licensure processes, and the modern craving for certainty in the New Drug discovery process led to a biomedical disaster— economically, politically, and interpersonally.

 

In this paper, I present the factors contributing to uncertainty and heightened exigence in the development of what I call “mef-Lariam” in a nod to Latourian hybridization. By tracing the history of the drug’s development process, I argue that definitional stasis around the NDA genre’s terms safe and effective undergird a dangerous ontological orientation to medicine that privileges an ethic of expediency. Finally, I argue that actor-network theory can help medical rhetors apply a more ethical, multiple view of medical research that could prevent the future licensure of toxic pharmaceuticals.

Sustainable development of an innovative enterprise in the US biopharmaceutical industry

Le 2 décembre 2016, 10:57 dans Humeurs 0

 

Medicilon offers fully integrated pharmaceutical services for the global scientific community. We focus on providing an exceptional client-centered experience and advancing the drug discovery process.

Email: Marketing@medicilon.com.cn                    Website: www.medicilon.com

The US biopharmaceutical industry is an industry set up expressly for identifying and producing pharmaceutical products for use in the medical treatment of disease. This industry has been unprofitable since its inception in 1970s. If the companies engaged in the biopharmaceutical industry cannot earn profit, the potential to benefit people all around the world with lifesaving medicines cannot be realized.

To find out the reasons of its unprofitability, we will focus on three characteristics of the drug development process: uncertainty, the lengthy process, and the high cost of drug development. To overcome all the three challenges, biopharmaceutical companies need strategic control, organizational integration and financial commitment (Lazonick 2007).

 

In the case study on Myriad Genetics Inc., a US biopharmaceutical firm, the strategists in the company had capability and incentives to transform resources into innovation in genetic research for some common cancers. Cumulative learning to generate expertise in these fields is a lengthy process that needs financial commitment until novel products are produced. Myriad's case also indicates that novel products created by a biopharmaceutical company may not be offered at a low price due to the market monopoly. It is arguable that the way a biopharmaceutical company pursues profits is consistent with the public need for innovation in biopharmaceuticals which means higher quality and lower price medical products.

Voir la suite ≫